EMJ GOLD: Pharma news, views and analysis
Join the EMJ GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm. Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.
info_outline
S12 E04: Richard Shotton on behaviour, bias and better pharma marketing
08/05/2026
S12 E04: Richard Shotton on behaviour, bias and better pharma marketing
In this episode, Isabel sits down with Richard Shotton, founder of Astroten and author of Hacking the Human Mind, to explore how behavioral science can help the pharmaceutical industry communicate more effectively and influence meaningful change. In the show, Richard explains why understanding what really drives human behaviour matters more than relying on what people say. He discusses the power of social proof, trusted messengers and concrete storytelling, and shares why making the right behaviour easier can have a greater impact than simply making a stronger argument. Guest bio Richard Shotton is a behavioural science expert, author, and founder of Astroten, a consultancy that helps organisations apply behavioural science to improve marketing effectiveness. He has worked with leading global brands including Google, Mondelez, Sky, and Santander, and is the author of bestselling books including , The , and . Richard is also a regular columnist for Marketing Week, co-host of the Behavioral Science for Brands podcast, and an honorary fellow of the IPA.
/episode/index/show/emgpodcast1/id/42326060
info_outline
S12 E03: Rafal Kaminski on epilepsy, innovation and equity
06/22/2026
S12 E03: Rafal Kaminski on epilepsy, innovation and equity
This content has been funded by Angelini Pharma. In this episode, Isabel sits down with Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, to explore how new science is reshaping brain health and what that means for patients. In the episode, Rafal reflects on his path into neuroscience and explains how Angelini is building its brain health pipeline, with a focus on epilepsy. He discusses the promise of new treatment approaches, the role of partnerships in driving progress and why better care depends on more than medicine alone. Guest bio Rafal Kaminski is Chief Scientific Officer at Angelini Pharma, where he leads the company's research and development strategy across small molecules, biologics and RNA-based therapies. He joined Angelini Pharma in 2022 after more than 20 years in senior R&D roles at UCB Pharma, Roche and Molecure Therapeutics, leading drug discovery programmes from early research into clinical development. A medical doctor with a PhD in Neuropharmacology, Rafal has authored more than 100 peer-reviewed publications and is an inventor on several patents. Outside of work, he is an avid music listener and vinyl collector and is married with one adult son.
/episode/index/show/emgpodcast1/id/41723275
info_outline
S12 E02: Rethinking multiple sclerosis care: The future of MS
03/26/2026
S12 E02: Rethinking multiple sclerosis care: The future of MS
In Part 3, Hideki Garren, Roche, shares a hopeful vision for slowing, stopping and ultimately preventing multiple sclerosis. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor’s degree from Caltech and an MD and PhD from UCLA.
/episode/index/show/emgpodcast1/id/41721860
info_outline
S12 E02: Rethinking multiple sclerosis care: Challenging old frameworks
03/24/2026
S12 E02: Rethinking multiple sclerosis care: Challenging old frameworks
In Part 2, Hideki Garren, Roche, discusses the challenge of measuring MS progression and the importance of better data, imaging and patient insight. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor’s degree from Caltech and an MD and PhD from UCLA.
/episode/index/show/emgpodcast1/id/41721825
info_outline
S12 E02: Rethinking multiple sclerosis care: From curiosity to care
03/23/2026
S12 E02: Rethinking multiple sclerosis care: From curiosity to care
This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients. In Part 1, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor’s degree from Caltech and an MD and PhD from UCLA.
/episode/index/show/emgpodcast1/id/41721795
info_outline
S12 E01: The 2026 pharma forecast: Unknowns and personal goals
02/19/2026
S12 E01: The 2026 pharma forecast: Unknowns and personal goals
In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they’re working towards in 2026. Speaker bios Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Senior Vice President of European Markets, BMS Emma oversees Bristol Myers Squibb’s operations across 19 countries of Europe, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. Omnichannel expert Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution. CEO, Healthcare Businesswomen’s Association Mary leads a global organisation that advances representative leadership, strengthens the talent pipeline for healthcare and life sciences, and fuels business growth across the sector.
/episode/index/show/emgpodcast1/id/40161740
info_outline
S12 E01: The 2026 pharma forecast: Opportunities and threats
02/17/2026
S12 E01: The 2026 pharma forecast: Opportunities and threats
As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year’s pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women’s health, alongside the key threats that could slow progress. Speaker bios Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Senior Vice President of European Markets, BMS Emma oversees BMS operations across 19 countries, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. CEO, Healthcare Businesswomen’s Association Mary leads a global organisation advancing the impact of women in healthcare, and is a prominent advocate for inclusive leadership, representative workforces and health equity.
/episode/index/show/emgpodcast1/id/40139370
info_outline
S11 E05: Pharma’s year in review 2025
12/23/2025
S11 E05: Pharma’s year in review 2025
This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress. Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to collaboration, innovation and scientific momentum. They also reflect on the lessons 2025 has taught them, and what those insights mean for patients, industry and the year ahead. Speaker bios Hanna Svanbäck Executive Director for Neuroscience, Eli Lilly With over 15 years at Eli Lilly, Hanna leads Neuroscience operations across the UK, Ireland and the Nordics, driving scientific innovation and patient-centred research. Jonathan Sackier Chairman, Medical Advisory Board, EMJ Jonathan is a surgeon by training and a founding partner of many start-ups in the medical technology space, as well as being the creator of the world’s first operating room robot. Yacin Marzouki Omnichannel expert Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.
/episode/index/show/emgpodcast1/id/39504675
info_outline
S11 E04: The gender health divide: Driving change
12/05/2025
S11 E04: The gender health divide: Driving change
In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too many women and why embedding sex- and gender-aware science from day one could accelerate fairer, more effective care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
/episode/index/show/emgpodcast1/id/39291220
info_outline
S11 E04: The gender health divide: Bias in practice
12/04/2025
S11 E04: The gender health divide: Bias in practice
In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinical trial exclusion continues to skew the science. Discover why representation isn't just a workforce issue: it’s a scientific necessity, and the first barrier we must dismantle to ensure better care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam’s global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
/episode/index/show/emgpodcast1/id/39253370
info_outline
S11 E04: The gender health divide: Tracing the gap
12/03/2025
S11 E04: The gender health divide: Tracing the gap
This week, Isabel sits down with Carol Pitcher-Towner, Senior Vice President and Head of Development Programmes, Alnylam Pharmaceuticals, to unpack the gender inequities that continue to tarnish modern healthcare. Together, they explore the realities behind unequal outcomes and the steps needed to build a more inclusive future for patients. In Part 1, Carol eveals the personal experiences that made gender inequity impossible to ignore and uncovers where today’s biggest gaps still exist. From disease areas where women are routinely misdiagnosed to the persistent blind spots shaping clinical practice, this episode exposes the uncomfortable truths that are still costing lives, and why fixing them can no longer be optional. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam’s global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
/episode/index/show/emgpodcast1/id/39253230
info_outline
E11 E03: Shaping the future of Alzheimer's care: The future of care
11/27/2025
E11 E03: Shaping the future of Alzheimer's care: The future of care
In Part 3, Hanna Svanbäck discusses the future of Alzheimer’s care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/39190540
info_outline
E11 E03: Shaping the future of Alzheimer’s care: Research and discoveries
11/26/2025
E11 E03: Shaping the future of Alzheimer’s care: Research and discoveries
In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer’s care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive news about prevention. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly’s long-standing commitment to advancing scientific innovation in this field. Hanna’s passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
/episode/index/show/emgpodcast1/id/39168675
info_outline
S11 E03: Shaping the future of Alzheimer’s care: Building a career in neuroscience
11/25/2025
S11 E03: Shaping the future of Alzheimer’s care: Building a career in neuroscience
This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer’s research. Together, they explore the latest breakthroughs, the challenges ahead and the strategies shaping the future of treatment and prevention. In Part 1 of the conversation, find out about Hanna's journey into neuroscience, her work in Alzheimer’s spanning three key markets and how her teams overcome the inevitable hurdles of brain-based drug discovery. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly’s long-standing commitment to advancing scientific innovation in this field. Hanna’s passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
/episode/index/show/emgpodcast1/id/39168590
info_outline
S11 E02: Transforming critical care through innovation: Future of advanced life support
11/14/2025
S11 E02: Transforming critical care through innovation: Future of advanced life support
In Part 3 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, talks about his outlook for the future of his field, his views on how the industry and clinicians can collaborate more effectively and the healthcare changes he is most excited about. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/39019305
info_outline
S11 E02: Transforming critical care through innovation: ECMO: Then and now
11/13/2025
S11 E02: Transforming critical care through innovation: ECMO: Then and now
In Part 2 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business, Medtronic, shares how ECMO has transformed over the decades and explores how clinicians and industry can work together to support the most vulnerable patients in intensive care. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he’s now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/39007165
info_outline
S11 E02: Transforming critical care through innovation: Building a career in MedTech
11/12/2025
S11 E02: Transforming critical care through innovation: Building a career in MedTech
This week, Isabel is joined by Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, for a deep-dive into the evolution and future of ECMO, innovation in critical care and the realities of leading in the MedTech space. In Part 1 of the interview, Giuseppe talks about what attracted him to the medical device industry, what his day-to-day role involves and what advice he would give to anyone considering joining the MedTech sector. Guest bio Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he’s now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/39007140
info_outline
S11 E01: Men's role in women's health: Repairing the gap
11/05/2025
S11 E01: Men's role in women's health: Repairing the gap
In Part 2 of this conversation, Robert Stewart, CEO, Theramex, explains how wider society can improve outcomes for women and reflects on the impact of decades of neglect in the field. Speaker bio Robert Stewart is CEO of Theramex, a global pharma company committed to supporting women’s health across contraception, fertility, menopause and osteoporosis. With over 30 years of industry experience, he has held senior leadership roles at Amneal Pharmaceuticals, Allergan and Abbott Laboratories. A passionate advocate for improving representation and access in women’s healthcare, Stewart is leading Theramex’s mission to empower women through innovative solutions and meaningful change across the heathcare landscape. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/38909765
info_outline
S11 E01: Men’s role in women’s health: Raising awareness and breaking taboos
11/04/2025
S11 E01: Men’s role in women’s health: Raising awareness and breaking taboos
The EMJ GOLD podcast returns. To launch the series, Isabel is joined by Robert Stewart, CEO, Theramex – a global pharmaceutical company solely dedicated to women’s health. In Part 1 of this discussion, they unpack what inspired Rob’s professional focus in this area and the role men can play in championing women’s health. Speaker bio Robert Stewart is CEO of Theramex, a global pharma company committed to supporting women’s health across contraception, fertility, menopause and osteoporosis. With over 30 years of industry experience, he has held senior leadership roles at Amneal Pharmaceuticals, Allergan and Abbott Laboratories. A passionate advocate for improving representation and access in women’s healthcare, Stewart is leading Theramex’s mission to empower women through innovative solutions and meaningful change across the heathcare landscape. Follow us on Instagram: @emj.gold
/episode/index/show/emgpodcast1/id/38909685
info_outline
S10 E10: Season 10’s insights, inspiration and ‘aha’ moments
08/06/2025
S10 E10: Season 10’s insights, inspiration and ‘aha’ moments
Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD’s guests this season, uncovering the challenges and opportunities shaping today’s pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season’s core themes, all backed by the latest industry data. Watch our featured guest’s full episodes:
/episode/index/show/emgpodcast1/id/37704915
info_outline
S10 E09: Bayer’s Dr Joana Reis on the promise of AI in breast cancer
07/29/2025
S10 E09: Bayer’s Dr Joana Reis on the promise of AI in breast cancer
How can industry close the screening gap in breast cancer? Find out in this episode, where Dr Joana Reis, Medical Affairs Breast Lead, Radiology, Bayer, explores some of the most significant challenges and opportunities in imaging today. Together, Jade and Joana discuss her initial interest in a career in radiology, the pivotal role of professional societies in accelerating innovation, how AI is shaping the future of the field and much more. A little more on EMJ GOLD’s guest… Dr Joana Reis was appointed Medical Affairs Breast Lead for radiology at Bayer in January of 2025. Before this, she was the Medical Affairs Lead for digital radiology at the company, where she developed strategies focusing on AI applications in imaging. Before joining Bayer, Joana worked as a Senior Consultant Breast Radiologist at Akershus University Hospital in Oslo, Norway.
/episode/index/show/emgpodcast1/id/37595505
info_outline
S10 E08: AbbVie’s Dr Daejin Adiboye on community and compassion in cancer care
07/22/2025
S10 E08: AbbVie’s Dr Daejin Adiboye on community and compassion in cancer care
Tune in as Dr Daejin Adiboye, Vice President, Therapeutic Area Head, Solid Tumor Oncology, AbbVie, explores both the evolution of cancer care and his leadership style over the last two decades. Together, Daejin and Jade discuss the lessons from his time in the clinic that shaped who he is today, the move to precision medicine in oncology, his work with the Cancer Support Community in San Francisco and much more. A little more on EMJ GOLD’s guest… Dr Daejin Abidoye serves as Vice President, Therapeutic Area Head for Solid Tumor Oncology at AbbVie. In this role, he is responsible for the clinical development of all assets in late oncology clinical development. His career includes over 20 years of experience in oncology, cancer research and drug development. Prior to joining AbbVie, Daejin was the Therapeutic Area Lead for Oncology Development and Clinical Research at Gilead Sciences. He has also held various roles at Seattle Genetics and Roche-Genentech. Dr. Abidoye is a board-certified oncologist with a career in clinical practice at Scripps Health in Southern California.
/episode/index/show/emgpodcast1/id/37506425
info_outline
S10 E07: Chiesi’s Shish Patel on COPD, the climate and improving care
07/15/2025
S10 E07: Chiesi’s Shish Patel on COPD, the climate and improving care
What is the environmental impact of respiratory illness? Find out in this episode of the EMJ GOLD podcast, where Shish Patel, Medical Director, Chiesi UK, joins Isabel to discuss the rising burden of COPD and the impact of respiratory care on the planet. Together, the two explore the diagnostic gap in COPD, improving the experience of people living with the disease, balancing health innovation with climate concerns and much more. A little more on EMJ GOLD’s guest… Shish Patel trained as a pharmacist and has worked in the pharmaceutical industry for over 30 years. Currently, he serves as Medical Director at Chiesi UK and Ireland, and he has held senior positions within medical and scientific functions at both affiliate and global level throughout his career. In addition to his significant time at Chiesi, Shish has held positions at GSK and Sanofi. Shish also holds key industry board positions including at the Prescription Medicines Code of Practice Authority and the ABPI.
/episode/index/show/emgpodcast1/id/37416175
info_outline
S10 E06: GSK’s Matt Mortimer-Ryan on behaviour-led pharma marketing
07/08/2025
S10 E06: GSK’s Matt Mortimer-Ryan on behaviour-led pharma marketing
In this week’s episode of the EMJ GOLD Podcast, Matt Mortimer Ryan, Senior Global Marketing Manager, Vaccines, GSK, shares his perspective on how understanding patients’ emotional drivers can unlock more impactful, insight-led disease awareness campaigns. Matt joins Isabel to discuss what true patient-centric marketing looks like in practice, how to translate behavioural insights into smarter strategies, the advice he’d give his younger self and much more. A little more on EMJ GOLD’s guest… Matt is a global marketing leader at GSK, driven by a passion for human-centered innovation in the pharmaceutical industry. With more than 20 years of experience at GSK, Pfizer and Danone, he combines his scientific curiosity with strategic creativity to accelerate meaningful outcomes for patients. The views expressed in this interview are Matt Mortimer-Ryan’s own and do not necessarily represent those of GSK.
/episode/index/show/emgpodcast1/id/37331940
info_outline
S10 E05: Analysing key trends in medical affairs in 2025
07/01/2025
S10 E05: Analysing key trends in medical affairs in 2025
In this special edition of the EMJ GOLD podcast, Isabel and Jade dive into the latest insights from recent contributors and EMJ’s own data to uncover what healthcare professionals really want from medical affairs. They explore the growing challenges of engaging HCPs, question whether there’s a gap between what HCPs say they want and what actually captures their attention and look ahead to what the future may hold. Tune in for expert insights from guests including Dr Donatello Crocetta, Bora Erdemli, Cécile Janssenswillen, Dr Natalia Barkalina and Dheepa Chari.
/episode/index/show/emgpodcast1/id/37236910
info_outline
E10 E04: Pfizer’s Richard Maughan on the future of access in the UK
06/24/2025
E10 E04: Pfizer’s Richard Maughan on the future of access in the UK
This week, the team is joined by Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, to explore how the UK is shaping access to medicine today, and what needs to change in the future. From healthy ageing to the economic cost of respiratory infections, they dive into what the UK is getting right, where it’s falling short and why access to medicine matters now more than ever. A little more on EMJ GOLD’s guest… Richard is Senior Director and Head of UK Policy and Public Affairs at Pfizer. His team works with public policymakers to deliver breakthroughs that change patients’ lives, spanning Pfizer’s broad medicines and vaccines portfolio, and deep science footprint. He is a member of Pfizer’s UK Senior Leadership Team and Europe Policy & Public Affairs Leadership Team. Prior to Pfizer, Richard was Head of UK Government Affairs for Eli Lilly and Company. He has also worked at the Confederation of British Industry (CBI), the UK’s leading business lobbying group. He studied Politics at the University of Edinburgh and the University of California Santa Cruz, and grew up in north-east England.
/episode/index/show/emgpodcast1/id/37131445
info_outline
E10 E03: BMS’ Anita Gandhi on a decade of change in hematology
06/17/2025
E10 E03: BMS’ Anita Gandhi on a decade of change in hematology
This National Blood Week, the team sit down with Anita Gandhi, Vice President, Translational Development, BMS, to explore the last decade of innovation in hematology and what lies ahead for the space. Together, Anita and Jade discuss Anita’s route into the pharmaceutical industry, the current unmet needs of patients with blood cancer, what the future of innovation looks like in hematology and what Anita’s HBA Rising Star Award means to her a decade on. A little more on EMJ GOLD’s guest… Anita is currently the Vice President of Translational Development at BMS, leading not only hematology translational development at the company, but solid tumour, immunology, cardiology and neurology as well. She has over 20 years of industry experience including drug discovery and translational development, and she was the recipient of the HBA Rising Star Award in 2015.
/episode/index/show/emgpodcast1/id/37131425
info_outline
S10 E02: Yacin Marzouki on disrupting the traditional omnichannel model
06/10/2025
S10 E02: Yacin Marzouki on disrupting the traditional omnichannel model
This week on the podcast, the team are joined by omnichannel engagement expert Yacin Marzouki, who shares his strategies on how to make omnichannel work for both pharmaceutical companies and healthcare professionals. Together, Yacin and Jade sit down in the studio to explore what it takes to harmonise omnichannel across an organisation, why content activation is still a major hurdle, how to make sure messaging truly and much more. Expect practical insights on operational excellence, the evolving role of AI and a fresh perspective on what success looks like across a product’s lifecycle. A little more on EMJ GOLD’s guest… Yacin Marzouki is a global omnichannel engagement lead on a mission to disrupt the industry’s approach to omnichannel. Within the pharmaceutical sector, he specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution. Yacin is dedicated to transforming brand plans into meaningful, measurable customer engagements, and is passionate about building high-performing, collaborative teams that deliver real impact.
/episode/index/show/emgpodcast1/id/36937810
info_outline
S10 E01: GSK’s Dheepa Chari on the evolving sphere of scientific communication
06/04/2025
S10 E01: GSK’s Dheepa Chari on the evolving sphere of scientific communication
The EMJ GOLD podcast is back for a new season! In the first episode of season 10, the team are joined by Dheepa Chari, Vice President and Head of Global Scientific Communications, GSK, to discuss the past, present and future of scientific communications. Together, Dheepa and Isabel explore her journey from biostatistics to biopharma leadership — and the lessons learned along the way. They discuss what great science communication looks like, where it’s heading next and why storytelling still matters in a digital-first world. Plus, expect practical insights on cross-functional collaboration and the growing role of AI. A little more on EMJ GOLD’s guest… Dheepa Chari is the Vice President and Head of Global Scientific Communications at GSK. Here, she leads strategy and execution across Oncology, Vaccines, Specialty Care and General Medicine, driving innovation in how scientific narratives are delivered across channels. Before joining GSK in 2024, Dheepa held senior posts at Pfizer, Amgen and Novartis in both clinical and communications roles. Outside of work, Dheepa brings stories to life in a different way - as a singer-songwriter who regularly performs in New York City.
/episode/index/show/emgpodcast1/id/36845680
info_outline
Season 9 highlights: GOLD Medal Moments
05/20/2025
Season 9 highlights: GOLD Medal Moments
Season 10 is on the horizon, but before we release our first episode, why not tune in to some of Isabel and Jade’s favourite moments from season 9? From leadership insights from top CEOs to navigating setbacks in R&D, there’s plenty to discover in this season’s batch of GOLD Medal Moments. As well as the EMJ GOLD team, you’ll hear from four former guests: , CEO, Lundbeck Pharmaceuticals , President and Managing Director, Galen Pharma , recipient of the Healthcare Businesswomen’s Association (HBA) STAR award for 2025 , Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim
/episode/index/show/emgpodcast1/id/36638185